| | Demographics | Experimental group, MyrLiq administration | Placebo group |
| | Number of volunteers | 184 | 184 | | Number of women (%) | 95 (51.6) | 95 (51.6) | | Number of men (%) | 89 (48.4) | 89 (48.4) | | Median age (range) | 38 (19–61) | 38 (19–63) | | Age range | | | | 18–35 | 21 (W), 9 (M) | 21 (W), 9 (M) | | 36–45 | 27 (W), 26 (M) | 27 (W), 26 (M) | | 46–60 | 29 (W), 30 (M) | 29 (W), 30 (M) | | Over 60 | 18 (W), 24 (M) | 18 (W), 24 (M) | | MyrLiq-PWD, 200 mg | 34 (W), 39 (M) | 34 (W), 39 (M) | | MyrLiq-PWD, 400 mg | 61 (W), 50 (M) | 61 (W), 50 (M) |
| | Baseline level | | | | Number for headaches | 33 (W), 17 (M) | 33 (W), 17 (M) | | Comparison with KE, IB, PA | | Number for fever-dependent pain | 12 (W), 19 (M) | 12 (W), 19 (M) | | Comparison with PA | | Number for joint pain | 23 (W), 20 (M) | 23 (W), 20 (M) | | Comparison with DI, KE | | Number for muscle aches | 14 (W), 22 (M) | 14 (W), 22 (M) | | Comparison with DI, KE, PA | | Number for lower back pain | 3 (W), 11 (M) | 3 (W), 11 (M) | | Comparison with DI, KE, TR, KT | | Number for menstrual cramps | 10 (W) | 10 (W) | | Comparison with KE, IB | | Number of tablets (days) | 1 (20) | 1 (20) | | Volunteers not completing the study (%) | 18 (9.9) | 33 (18.2) | | Women not completing the study (%) | 11 (11.4) | 23 (24.1) | | Men not completing the study (%) | 7 (8.3) | 10 (11.8) |
|
|
